Impact of central nervous system involvement in AML on outcomes after allotransplant and utility of pretransplant cerebrospinal fluid assessment.
Shruti PremEshetu G AtenafuJose AvenaRhida BautistaArjun LawWilson LamFotios V MichelisDennis Dong Hwan KimAuro ViswabandyaJeffrey Howard LiptonJonas MattssonRajat KumarPublished in: European journal of haematology (2019)
CNS-AML is not an independent risk factor for survival after allo-HCT, but can be associated with higher relapse rates. Pretransplant CSF assessment has low yield in detecting new CNS disease pretransplant in AML.